Pediatric Nephrology

, Volume 26, Issue 12, pp 2111–2119 | Cite as

Can bisphosphonates play a role in the treatment of children with chronic kidney disease?

  • Dieter HaffnerEmail author
  • Dagmar-Christiane Fischer


In patients with chronic kidney disease (CKD) renal osteodystrophy, in the form of either low- or high-turnover bone disease, is quite common. While renal transplantation is expected to reverse renal osteodystrophy, long-term treatment with glucocorticoids before and/or after transplantation may lead to osteoporosis instead. Osteoporosis is defined as a skeletal disease with low bone mineral density, microarchitectural deterioration, and concomitant fragility. In adults, bisphosphonates are widely used to treat osteoporosis and other diseases associated with excessive bone resorption. In pediatric CKD patients the efficacy and safety of these drugs have not yet been addressed adequately and thus no evidence-based recommendations regarding the optimal type of bisphosphonate, dosage, or duration of therapy are available. Furthermore, while in adults the determination of areal bone mineral density is sufficient to diagnose osteoporosis, this is not the case in children. Instead, in pediatric patients, careful morphological assessment of bone structure and formation is required. Indeed, data from studies with uremic rats indicated that bisphosphonates, via a deceleration of bone turnover, have the potential not only to aggravate pre-existing adynamic bone disease, but also to impair longitudinal growth. Thus, the widespread use of bisphosphonates in children with CKD should be discouraged until the risks and benefits have been carefully elucidated in clinical trials.


Bisphosphonate Chronic kidney disease Renal osteodystrophy Osteoporosis 


  1. 1.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119PubMedCrossRefGoogle Scholar
  2. 2.
    Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105PubMedCrossRefGoogle Scholar
  3. 3.
    Mitsnefes MM (2008) Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 23:27–39PubMedCrossRefGoogle Scholar
  4. 4.
    Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197PubMedCrossRefGoogle Scholar
  5. 5.
    Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis—from clinical observation towards molecular understanding. Osteoporos Int 18:251–259PubMedCrossRefGoogle Scholar
  6. 6.
    Peck WA, Burckhardt P, Christiansen C, Fleisch HA, Genant HK, Gennari C, Martin TJ, Martini L, Morita R, Ogata E, Rapado A, Shulman LE, Stern PH, Young RTT (1993) Consensus Development Conference—Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am J Med 94:646–650CrossRefGoogle Scholar
  7. 7.
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRefGoogle Scholar
  8. 8.
    Ward LM, Glorieux FH (2003) The spectrum of pediatric osteoporosis. In: Glorieux FH, Pettifor JM, Jüppner H (eds) Pediatric bone biology and disease, vol 1. Elsevier Science, San Diego, pp 401–442Google Scholar
  9. 9.
    Grenda R (2010) Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 25:747–752PubMedCrossRefGoogle Scholar
  10. 10.
    Bianchi ML (2002) Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 70:384–390PubMedCrossRefGoogle Scholar
  11. 11.
    Leonard MB (2007) Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 119 [Suppl 2]:S166–S174PubMedCrossRefGoogle Scholar
  12. 12.
    Shaw NJ (2008) Management of osteoporosis in children. Eur J Endocrinol 159 [Suppl 1]:S33–S39PubMedCrossRefGoogle Scholar
  13. 13.
    Moe SM, Drueke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chron Kidney Dis 14:3–12CrossRefGoogle Scholar
  14. 14.
    Hruska KA, Choi ET, Memon I, Davis TK, Mathew S (2010) Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 25:769–778PubMedCrossRefGoogle Scholar
  15. 15.
    El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA (2004) Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 8:357–361PubMedCrossRefGoogle Scholar
  16. 16.
    Kodras K, Haas M (2006) Effect of kidney transplantation on bone. Eur J Clin Invest 36 [Suppl 2]:63–75PubMedCrossRefGoogle Scholar
  17. 17.
    Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731PubMedCrossRefGoogle Scholar
  18. 18.
    Weber LT, Mehls O (2010) Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol 25:3–5PubMedCrossRefGoogle Scholar
  19. 19.
    Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045PubMedCrossRefGoogle Scholar
  20. 20.
    Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80–100PubMedCrossRefGoogle Scholar
  21. 21.
    Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9 [Suppl 4]:3–13PubMedCrossRefGoogle Scholar
  22. 22.
    Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O’Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617–625PubMedCrossRefGoogle Scholar
  23. 23.
    Neven EG, De Broe ME, D’Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580–582PubMedCrossRefGoogle Scholar
  24. 24.
    Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915PubMedGoogle Scholar
  25. 25.
    Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824PubMedCrossRefGoogle Scholar
  26. 26.
    Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356–363PubMedCrossRefGoogle Scholar
  27. 27.
    Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233PubMedCrossRefGoogle Scholar
  28. 28.
    Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57–68PubMedCrossRefGoogle Scholar
  29. 29.
    Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264PubMedCrossRefGoogle Scholar
  30. 30.
    Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119 [Suppl 2]:S150–S162PubMedCrossRefGoogle Scholar
  31. 31.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRefGoogle Scholar
  32. 32.
    Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577–1583PubMedCrossRefGoogle Scholar
  33. 33.
    Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H (2005) Effect of etidronate on aortic calcification and bone metabolism in calcitoriol-treated rats with subtotal nephrectomy. J Pharmacol Sci 99:89–94PubMedCrossRefGoogle Scholar
  34. 34.
    Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S (2005) Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 5:174–181PubMedGoogle Scholar
  35. 35.
    Brown JJ, Zacharin MR (2005) Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 41:553–557PubMedCrossRefGoogle Scholar
  36. 36.
    Wright HL, McCarthy HS, Middleton J, Marshall MJ (2009) RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2:56–64PubMedCrossRefGoogle Scholar
  37. 37.
    Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K (2009) Osteoporosis: an age-related and gender-specific disease—a mini-review. Gerontology 55:3–12PubMedCrossRefGoogle Scholar
  38. 38.
    Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29:293–299PubMedCrossRefGoogle Scholar
  39. 39.
    Bianchi ML, Baim S, Bishop NJ, Gordon CM, Hans DB, Langman CB, Leonard MB, Kalkwarf HJ (2010) Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 25:37–47PubMedCrossRefGoogle Scholar
  40. 40.
    Leonard MB (2007) A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol 22:1815–1824PubMedCrossRefGoogle Scholar
  41. 41.
    Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190PubMedCrossRefGoogle Scholar
  42. 42.
    Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669–2676PubMedCrossRefGoogle Scholar
  43. 43.
    Fan SL, Cunningham J (2001) Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens 10:581–588PubMedCrossRefGoogle Scholar
  44. 44.
    Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215–222PubMedCrossRefGoogle Scholar
  45. 45.
    Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59–64PubMedCrossRefGoogle Scholar
  46. 46.
    Sellers E, Sharma A, Rodd C (1998) The use of pamidronate in three children with renal disease. Pediatr Nephrol 12:778–781PubMedCrossRefGoogle Scholar
  47. 47.
    Shaw NJ, Bishop NJ (2005) Bisphosphonate treatment of bone disease. Arch Dis Child 90:494–499PubMedCrossRefGoogle Scholar
  48. 48.
    Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 20:150–157PubMedCrossRefGoogle Scholar
  49. 49.
    WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129Google Scholar
  50. 50.
    Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, Munns C, Wenkert D, Zeitler P (2008) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 11:22–28PubMedCrossRefGoogle Scholar
  51. 51.
    Saland JM, Goode ML, Haas DL, Romano TA, Seikaly MG (2001) The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. Am J Transplant 1:243–250PubMedCrossRefGoogle Scholar
  52. 52.
    K/DOQI (2003) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201Google Scholar
  53. 53.
    K/DOQI (2005) Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1–S103Google Scholar
  54. 54.
    Christoforidis A, Printza N, Gkogka C, Siomou E, Challa A, Kazantzidou E, Kollios K, Papachristou F (2010) Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J Bone Miner Metab. doi: 10.1007/s00774-010-0220-1 PubMedGoogle Scholar
  55. 55.
    Camacho PM, Lopez NA (2008) Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med 46:1345–1357PubMedCrossRefGoogle Scholar
  56. 56.
    Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92:443–449PubMedCrossRefGoogle Scholar
  57. 57.
    Singer FR, Eyre DR (2008) Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 75:739–750PubMedCrossRefGoogle Scholar
  58. 58.
    Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11:281–294PubMedCrossRefGoogle Scholar
  59. 59.
    Loud KJ, Gordon CM (2006) Adolescent bone health. Arch Pediatr Adolesc Med 160:1026–1032PubMedCrossRefGoogle Scholar
  60. 60.
    Acott PD, Wong JA, Lang BA, Crocker JF (2005) Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 20:368–373PubMedCrossRefGoogle Scholar
  61. 61.
    Kim SD, Cho BS (2006) Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 102:c81–c87PubMedCrossRefGoogle Scholar
  62. 62.
    Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatol (Oxf) 44:813–818CrossRefGoogle Scholar
  63. 63.
    Ward LM, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury, Rauch F, Tugwell P, Moher D (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev CD005324Google Scholar
  64. 64.
    Fan SL, Almond MK, Ball E, Evans K, Cunningham J (2000) Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684–690PubMedGoogle Scholar
  65. 65.
    Palmer SC, McGregor DO, Strippoli GF (2007) Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev CD005015Google Scholar
  66. 66.
    Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T (2007) Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 22:1601–1607PubMedCrossRefGoogle Scholar
  67. 67.
    Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S (2007) Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 22:1593–1600PubMedCrossRefGoogle Scholar
  68. 68.
    Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241–247PubMedCrossRefGoogle Scholar
  69. 69.
    Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680–688PubMedGoogle Scholar
  70. 70.
    Bachrach LK, Ward LM (2009) Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94:400–409PubMedCrossRefGoogle Scholar
  71. 71.
    Machado CE, Flombaum CD (1996) Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 45:175–179PubMedGoogle Scholar
  72. 72.
    Torregrosa JV, Moreno A, Mas M, Ybarra J, Fuster D (2003) Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int Suppl S88–S90Google Scholar
  73. 73.
    Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285–290PubMedGoogle Scholar
  74. 74.
    Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M (2007) Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 47:942–950PubMedCrossRefGoogle Scholar
  75. 75.
    Beigel AE, Rienhoff E, Olbricht CJ (1995) Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 10:2266–2268PubMedGoogle Scholar
  76. 76.
    Bergner R, Dill K, Boerner D, Uppenkamp M (2002) Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 17:1281–1285PubMedCrossRefGoogle Scholar
  77. 77.
    Buttazzoni M, Rosa Diez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L (2006) Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 11:197–200CrossRefGoogle Scholar
  78. 78.
    Rauch F, Schonau E, Glorieux FH (2000) Bisphosphonates—pediatric use. Monatsschr Kinderheilkd 148:334–341CrossRefGoogle Scholar
  79. 79.
    Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831–847PubMedCrossRefGoogle Scholar
  80. 80.
    Haffner D, Fischer DC (2010) Bone cell biology and pediatric renal osteodystrophy. Minerva Pediatr 62:273–284PubMedGoogle Scholar
  81. 81.
    Fischer DC, Jensen C, Rahn A, Salewski B, Kundt G, Behets GJ, D’Haese P, Haffner D (2011) Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol 26:111–117PubMedCrossRefGoogle Scholar
  82. 82.
    Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534–540PubMedCrossRefGoogle Scholar
  83. 83.
    Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D’Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  1. 1.Department of PediatricsUniversity Hospital of RostockRostockGermany

Personalised recommendations